Curis, Inc. (CRIS) CEO Jim Dentzer on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/17/21
Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual MeetingPRNewsWire • 03/10/21
Curis to Release Fourth Quarter 2020 Financial Results and Hold Conference Call on March 16, 2021PRNewsWire • 03/09/21
Curis: Differentiated IRAK4 Inhibitor To Drive Value Creation In The Near TermSeeking Alpha • 03/01/21
Small Cap Momentum Stories to Watch (NASDAQ: BLNK) (OTC US: MMEDF) (OTC US: CLKA) (NASDAQ: CRIS)OTC PR Wire • 12/16/20
Curis skyrockets 448% after encouraging phase 1 data for leukemia treatment (CRIS)Business Insider • 12/08/20
Curis stock more than triples on massive volume after upbeat leukemia treatment trial resultsMarket Watch • 12/08/20
Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's LymphomaPRNewsWire • 12/07/20
Curis, Inc. (CRIS) CEO Jim Dentzer on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/11/20
Curis, Inc. (CRIS) CEO Jim Dentzer On Q3 2020 Results - Quick Version Earnings Call TranscriptSeeking Alpha • 11/10/20